HAVCR2 and acute lymphoblastic leukemia: In a previous work by our group, we identified TIM-3 expression on bone marrow T cells as a marker of dismal prognosis in pediatric ALL patients and showed that TIM-3 overexpression can inhibit antileukemic T-cell responses mediated by Blinatumomab (19).